Simparica For Dogs 22.1-44 lbs (10.1-20 kg)

Description

Simparica For Dogs 22.1-44 lbs (10.1-20 kg) is a monthly oral chewable tablet manufactured by Zoetis, delivering treatment and prevention of fleas and six tick species within a single dose. The 22.1–44 lbs variant contains 40 mg sarolaner per tablet, providing a minimum effective dose of approximately 0.91 mg/lb (2 mg/kg). This weight band covers medium-breed dogs, including breeds such as Beagles, Cocker Spaniels, and Border Collies that fall within this range at adult weight.

Recommended for

Dogs weighing 22.1–44 lbs (10.1–20 kg), 6 months of age and older.

Indication/Coverage

For dogs suffering from, or at risk from, mixed parasitic infections:

• Flea treatment and prevention: Kills adult Ctenocephalides felis on the host and prevents reinfestation; flea egg deposition is blocked for a minimum of 35 days per dose, arresting the environmental life cycle at the source.
• Lone star tick treatment and control: Eliminates adult Amblyomma americanum with efficacy sustained across the full 30-day dosing interval.
• Gulf Coast tick treatment and control: Eliminates adult Amblyomma maculatum infestations for one month per dose.
• American dog tick treatment and control: Eliminates adult Dermacentor variabilis infestations for one month per dose.
• Black-legged tick treatment and control: Eliminates adult Ixodes scapularis for one month; additionally indicated for prevention of Borrelia burgdorferi infection through tick elimination before the bacterial transmission window opens.
• Brown dog tick treatment and control: Eliminates adult Rhipicephalus sanguineus infestations for one month per dose.
• Asian longhorned tick treatment and control: Eliminates adult Haemaphysalis longicornis infestations for one month per dose.

Key Benefits

The following are specific to the 22.1–44 lbs (10.1–20 kg) tablet, based on Zoetis-labeled efficacy data:

• Weight band entry precision: The 40 mg tablet delivers exactly 2 mg/kg at a body weight of 44 lb (20 kg), achieving the minimum therapeutic concentration at the upper end of this range without deviation.
• Complete U.S. tick spectrum: A single monthly dose addresses all six tick species of current regulatory and epidemiological concern in the United States, including the invasive Haemaphysalis longicornis.
• Three-hour flea kill initiation: Laboratory data confirm sarolaner begins eliminating adult fleas within 3 hours of oral administration, with 96.2% or greater reduction documented within 8 hours post-infestation.
• Egg deposition suppression: Fleas in contact with treated dogs fail to deposit viable eggs for at least 35 days, preventing larval buildup in domestic environments rather than reducing adult flea counts on the dog alone.
• Lyme disease vector control: Simparica eliminates Ixodes scapularis before Borrelia burgdorferi transmission can occur, providing a documented layer of Lyme disease protection in endemic U.S. regions.
• Proven cumulative efficacy: A 90-day U.S. field study recorded 99.4% flea reduction at Day 30, 99.8% at Day 60, and 100% at Day 90, demonstrating that protection strengthens with continued monthly treatment.
• Systemic delivery advantage: Absorption via the gastrointestinal tract makes efficacy independent of coat condition, bathing frequency, or water exposure, unlike topical formulations where skin-surface distribution varies by coat type.

Caution

Hazards to Humans

Keep this tablet out of reach of children. If it is accidentally swallowed by a person, seek medical advice immediately. Wash hands thoroughly with soap and water after handling, and avoid contact with food, food preparation areas, or animal feed.

Hazards to Domestic Animals

For oral administration in dogs only; this tablet is not labeled for use in cats. Indicated for dogs 6 months of age and older with a confirmed minimum weight of 22.1 lbs (10.1 kg). Consult a veterinarian before administering to debilitated, aged, pregnant, or nursing animals. Rare individual hypersensitivity reactions have been documented. Sarolaner is an isoxazoline-class compound; since 2018, the FDA has mandated neurological adverse event warnings on all isoxazoline-class products. Dogs with a seizure history or pre-existing neurological condition require veterinary clearance before use. Drug interaction data for concurrent medications is not fully established; seek veterinary input before combining with other treatments.

Possible Side Effects

Following each monthly dose, monitor your dog for a minimum of 24 hours, particularly during the initial 3 hours as sarolaner nears peak plasma concentration.

The adverse reactions below are drawn from Zoetis controlled trial data and post-approval FDA CVM reporting for sarolaner, listed in decreasing order of documented frequency:

• Vomiting: Recorded in 0.95% of sarolaner-treated dogs in the U.S. field study; observe for vomiting within the first 3 hours of administration when absorption remains active, and continue monitoring for any adverse reactions across the following 24 hours, contacting your veterinarian if either occurs.
• Diarrhea: Present in 0.63% of treated dogs during the controlled clinical phase; post-approval reports additionally document cases with blood in the stool.
• Lethargy: Observed in 0.32% of treated dogs in the field study and reflected in post-market adverse event submissions to the FDA.
• Neurologic signs: Tremors, ataxia, diminished conscious proprioception, and seizures have been documented across the isoxazoline class, including in dogs without pre-existing neurological conditions; this risk applies to dogs in the 22.1–44 lb range.
• Additional post-approval events: Anorexia, pruritus, hypersalivation, and hyperactivity have been identified through ongoing FDA CVM adverse drug experience surveillance for sarolaner.